Peer review of critical care pharmacy services

Introduction

These quality standards have been developed to support the critical care pharmacists in ensuring a high quality of care across the Networks that form the Midlands Critical Care Networks. The three regions include the Birmingham and Black Country, Central England and the North West Midlands.

The standards aim to be:

- Open, transparent, fair and equitable
- Standardised and consistent across the "patch"
- Supported by a number of accepted referencing documents

No single set of standards exists that encompasses the whole pharmacy service provided to critical care. These standards have been developed from GPICS,(1) the DH report 'Adult critical care: specialist pharmacy practice',(2) the Birmingham and Black Country Critical Care Network peer review documentation and the American College of Clinical Pharmacy.(3) Overall these describe the ideal service provided to critical care by pharmacy.

The emphasis of the peer review process is not to find blame, but rather to identify areas of strong and weak practice.

The benefit of pharmacy involvement in critical care has been well documented. A paper from 2002 reviewed the literature pertaining to clinical pharmacy in North America and provided a summary of benefits that had been identified.(4) More recently a study has been conducted in UK critical care units, PROTECTED-UK, which describes the work of clinical pharmacists on critical care.(5-7) A survey, conducted in 2015, describes the pharmacy workforce demographics for critical care,(8) and an earlier one in 2014 describes the activity of pharmacist prescribers in critical care.(9)

Contents

Part One Demographics of previous financial year or equivalent

- Unit
- Workload
- Drug Expenditure
- Other drug cost data routinely presented

Part Two Consolidated Standards

- Fundamental Staffing Standards
- Desirable Staffing Standards
- Fundamental Pharmacist Activities
- Desirable Pharmacist Activities
- Optimal Pharmacist Activities
- Fundamental Pharmacy and Hospital Services
- Desirable Pharmacy and Hospital Services
- Optimal Pharmacy and Hospital Services

Part Three Post Visit Comments

- General Comments
- Immediate Risk
- Concerns
- Further Consideration
- Good Practice

Midlands	Critical	Care &	Trauma	Networks	NHS
Midiands	Cittical	Care G	Hauma	METANOLKS	11113

Part One - Demographics of previous financial year or equivalent

i ait one being	i apines e	i previous illialiciai year or equ	aivaiciic						
Unit	Туре		Lev	vel 3 or L3	equivalent		Level 2		Total
	Number o	f Operational beds							
		- tick all that are appropriate	Cardiac ☐ N	Neuro□ (General 🗌	Medical□	Paeds□ Surgic	al□ Burns	s Other
Workload		ut - Number of admissions							
		ate time period used)							
		Number of patient bed days (or							
	equivalen								
Pharmacy	Normal of	pening time of pharmacy:							
Drug expenditure			List the	top 20 dru	ugs spend -	in order (sn	apshot only)		
	Top 20		Name				Cost –	- previous fi	inancial year or equivalent)
	_								
	1								
	3								
	5								
	6								
	7								
	8								
	9								
	10								
	11								
	12								
	13								
	14								
	15								
	16								
	17								
	18								
	19								
	20								
Other drug cost	Provide de	etail;							
data routinely			_						
presented?	How is thi	s presented and who is it presented	to?						
				Total Arres	ual Dava Fo	dit			
				i otai Ann	ual Drug Ex	penaiture			

<u>Part Two - Consolidated Standards</u>

Fundamental Staffing Standards			Evidence Required	Self-Assessment Compliance Y/N	Trust Comments	Review Team Compliance Y/N	Review Team Comments
1		Acute Trusts should fund at least 0.1 WTE specialist clinical pharmacist (8a or above) for each single Level 3 bed and for every two Level 2 beds. Dedicated time for critical care patients with few other commitments outside the ITU area See GPICS for further explanation	List Grade and WTE allocated to critical care				
2	Working pattern	Daily sessional support to critical care should be provided and ideally available 7 days per week. A minimum service should be provided 5 days per week (Monday – Friday).	List frequency and duration of sessional support Staffing rota Ward list				
3	Level 3 Patients	A competent critical care pharmacist should be an integral part of the Critical Care team. This person should also provide advice and support to pharmacy and clinical colleagues working at all levels of critical illness, and be the key pharmacist liaising with the outreach team. If the pharmacist has the minimum competencies (Foundation Level), then they must have access to a more senior specialist critical care pharmacist (for advice and referrals)	Discussion with staff RPS/UKCPA credentialing				
4	Level 2 Patients	The pharmaceutical care for the Critical Care patient should be provided by either a competent specialist critical care pharmacist or another experienced pharmacist working in close collaboration.	Discussion with staff RPS/UKCPA credentialing				
5	Level 1 Patients	Patients are often seen in non-critical care areas. It is essential that all clinical pharmacists have the basic skills to care for level 1 patient's. The critical care specialist pharmacist has a key role in optimising this care by educating and supporting colleagues	Discussion with staff				

Fun	damental Pharmacist Activities	Evidence Required	Self-Assessment Compliance Y/N	Comments	Review Team Compliance Y/N	Review Team Comments
6	Sufficient pharmacy technician staff to provide supporting roles e.g. MMT, Technician top-up service, frequency?	Discussion with staff				
		Staff rota/list				
7	 Agreed arrangements for units to ensure: a. Availability of non-stock drugs within 1 hour b. Availability within 1 hour of additional stock items at times of peak demand 	Discussion with staff Protocol/ Policies				
8	Outside normal working hours, access should be available to a pharmacist for advice and medication	SOP Protocol/Policies Discussion with staff				
9	Evaluation of drug therapies for appropriate indications, dosage, interactions, allergies	Discussion with staff Written evidence Review charts				
10	Monitor patients pharmacotherapeutic regimen for effectiveness and Adverse Drug Events (ADE's); intervene as needed	Discussion with staff Written evidence Review charts				
11	Review patient drug history and complete medicines reconciliation to optimise maintenance drugs	Discussion with staff Written evidence Review charts/notes				
12	Use medical records as recorded means of communicating with other healthcare professionals and to document specific pharmacotherapeutic recommendations	Discussion with staff Written evidence Review charts/notes				
13	Provide drug information when indicated	Discussion with staff Written evidence Review charts				
14	Contribute to and maintain departmental policies and procedures related to safe and effective use of drugs in Critical Care	Policies/procedures				
15	Provide consultation to relevant hospital committees relating to critical care pharmacotherapy issues	Meeting minutes				
16	Ensure effective and efficient cost-containment of drugs budget and identify cost improvements, which are communicated to relevant critical care staff.	Budget evidence of cost control/saving				
17	Contribute to quality assurance and audit programmes to enhance pharmaceutical care	Discussion with staff Written evidence Audit				
18	Critically evaluate newly published evidence and share the information with critical care colleagues	Discussion with staff Journal evidence Membership				
19	Deal with the implementation of national guidance relating to	Discussion with staff				

	avitical care a S. NICE	Muittan avidanas		1		1
	critical care e.g. NICE	Written evidence				
20	Is involved in unit clinical governance meetings or equivalent	Meeting minutes				
21	Makes regular ward rounds as member of multi-disciplinary team	Staff rota				
	providing pharmacotherapeutic management for all critical care	Discussion with staff				
	patients	Written evidence				
Des	irable Pharmacist Activities	Evidence	Self-Assessment	Comments	Reviewing	Reviewing Team
			Compliance Y/N		Team	Comments
			, , , ,		Compliance	
					Y/N	
22	Liaise with dietician/nutrition team to ensure optimal nutrition	Discussion with staff				
	regimen	Written evidence				
23	Identify Adverse Drug Events, assist in their management and	Discussion with staff				
	develop process improvements to reduce drug errors and	Written evidence				
	preventable ADE's					
24	Delirium Screening – interventions should include both	Discussion with staff				
	Pharmacological and non-pharmacological considerations and highly	Written evidence				
	trained pharmacists who should provide assessments and strategies					
	for patients identified as suffering from delirium					
25	Provide drug therapy related education to Critical Care team and	Education				
	strategies to support non-medical prescribers in critical care.	programmes				
26	Provide formal instructional and educational lectures for health care	Education				
	professionals	programmes				
27	Coordinate the development and implementation of drug therapy	Protocol/pathway				
	protocols and/or critical care pathways to optimise benefits of drug	evidence				
	therapy					
Opt	imal Pharmacist Activities	Evidence	Self-Assessment	Comments	Reviewing	Reviewing Team
			Compliance Y/N		Team	Comments
					Compliance	
					Y/N	
28	Participate in research design and data analysis where applicable	Research evidence				
29	Actively involved in critical care pharmacotherapy research	Research evidence				
30	Assist Critical Care Clinicians in discussions with family/patients in	Discussion with staff				
	making informed decisions regarding treatment options					
31	Provide formal accredited educational sessions	Education				
		programmes				
32	Develop and implement pharmacy staff training programmes for	Training programmes				
	personnel working in Critical Care					
33	Independently investigate or collaborate with other Critical Care	Discussion with staff				
	clinicians to evaluate the impact of guidelines and/or protocols for	Written evidence				
	drug administration and management of common diseases					

34	Is proactive in designing, prioritising and promoting new pharmacy	Discussion with staff		
	programmes and services	Written evidence		
35	Report results of clinical research to relevant local, regional and	Discussion with staff		
	national groups	Written evidence		
		Meeting minutes		
36	Publish in peer-reviewed pharmacy and medical literature as a result	Publications		
	of research involvement			
37	Participate in unit's morbidity and mortality reviews	Discussion with staff		
		Written evidence		

Fun	damental Pharmacy and Hospital Services	Evidence	Self-Assessment	Comments	Reviewing Team	Reviewing Team
		Evidence	Compliance Y/N		Compliance Y/N	Comments
38	Systems are in place to:	Discussion with staff				
	a) create and maintain patient drug profile					
	b) easily obtain patient laboratory data	Demonstration				
	c) alert healthcare professionals to drug allergies					
	d) alert healthcare professionals to drug-drug, drug-nutrient					
	interactions					
	If you have an electronic system you can:					
Ī	e) alert healthcare professionals to maximum dosage limits					
	N.B if electronic system used for all of above they should be					
	integrated.					
39	Quality assurance systems are in place to verify accuracy of manual	Discussion with staff				
l	drug administration records	Written evidence				
		Policies				
40	Drug storage space on Critical Care is regularly assessed to identify	Discussion with staff				
l	where efficiency can be improved upon	Written evidence				
		Logs				
41	Drug procurement, storage, inventory and distribution are under the	Discussion with staff				
42	supervision of the pharmacist	Written evidence				
42	The Pharmacy department is represented on relevant Trust committees	Meeting minutes				
Des	irable Pharmacy and Hospital Services	Evidence	Self-Assessment	Comments	Reviewing Team	Reviewing Team
Des	nable Filathlacy and Hospital Services	LVIGETICE	Compliance Y/N	Comments	Compliance Y/N	Comments
43	The Trust information system is computerised and can comply with	Discussion with staff	compliance 1710		Compilative 1711	Comments
	requirements of no. 41 in addition to:	Written evidence				
	a) alert healthcare professionals to disease state-drug					
	interaction					
	b) provide intravenous admixture information					
	c) provide online drug and poison information					
	d) document clinical pharmacy patient care interventions					
44	Computerised drug administration records are generated, manual	Discussion with staff				
	records are only used in emergency (off line) situations	Written evidence				
45	Pharmacotherapeutic / pharmacokinetic and nutrition consultation	Staff rota				
l	available	Discussion with staff				
	24 hrs/day 7 days/week	Written evidence				
Opt	imal Pharmacy and Hospital Services	Evidence	Self-Assessment Compliance Y/N	Comments	Reviewing Team Compliance Y/N	Reviewing Team Comments
46	Parenteral products are pre-prepared in pharmacy and delivered at	Discussion with staff				
1	regular scheduled interval 7 days/week	Written evidence				
			•	•		•

Midland	s Critical	Care &	Trauma	Networks	NHS
---------	------------	--------	--------	----------	-----

	a) Parenteral Nutrition b) Cytotoxics c) CIVAS			
47	The Computerised Trust information system serving Critical Care has	Discussion with staff		
	the following additional capabilities:	Written evidence		
	a) direct clinician drug prescribing at the patient's bedside	Demonstration		
	b) interfaces with bedside clinical information systems			

st Visit comments	
mediate Risks	
neral Concerns	
ther consideration / General comments	
od practice / Significant Improvements	\dashv

References

- 1. Guidelines for the Provision of Intensive Care Services. London: FICM/ICS; 2016.
- Department of Health. Adult Critical Care: Specialist Pharmacy Practice. London; 2005 01 Jul 2005.
- 3. Rudis MI, Brandl KM. Position paper on critical care pharmacy services. Crit Care Med. 2000;28(11):3746-50.
- 4. Kane SL, Weber RJ, Dasta JF. The impact of critical care pharmacists on enhancing patient outcomes. Intensive Care Med. 2003;29(5):691-8.
- 5. Shulman R, McKenzie CA, Landa J, Bourne RS, Jones A, Borthwick M, et al. Pharmacist's Review and Outcomes: Treatment Enhancing Contributions Tallied, Evaluated and Documented (PROTECTED-UK). Journal of Critical Care. 2015;30:808-13.
- 6. Landa J, McKenzie C, Shulman R, Bates I. Analysis of factors influencing critical care pharmacists impact in the intensive care unit (ICU) and weekend service outcomes. International Journal of Pharmacy Practice. 2014;22(Supplement 2):44.
- 7. Rudall N, McKenzie C, Landa J, Bourne RS, Bates I, Shulman R. PROTECTED-UK Clinical pharmacist interventions in the UK critical care unit: exploration of relationship between intervention, service characteristics and experience level. International Journal of Pharmacy Practice. 2017;25(4):311-9.
- 8. Borthwick M, Barton G, Bourne RS, McKenzie C. Critical care pharmacy workforce: UK deployment and characteristics in 2015. International Journal of Pharmacy Practice [Internet]. 2017 7/11/17:[n/a-n/a pp.]. Available from: http://dx.doi.org/10.1111/ijpp.12408.
- 9. Bourne RS, Whiting P, Brown LS, Borthwick M. Pharmacist independent prescribing in critical care: results of a national questionnaire to establish the 2014 UK position. International Journal of Pharmacy Practice. 2016;24(2):104-13.